Results from ongoing randomized clinical trials investigating the optimal sequencing and combinations including these targeted agents with biomarker-based population refinement are warranted to fully optimize combinatorial strategies targeting PI3K/AKT/mTOR, CDK4/6 and ER in ER+ advanced breast cancer. This evidence concerns the gene MTOR and breast cancer.